P53 and autophagy contribute to dasatinib resistance in primary CLL lymphocytes

41Citations
Citations of this article
52Readers
Mendeley users who have this article in their library.
Get full text

Abstract

B-cell chronic lymphocytic leukemia (CLL) is the most common leukemia in adults and there is no cure for the disease. Although dasatinib is cytotoxic to primary CLL lymphocytes in vitro, the drug has been shown to be active in a small percent of CLL patients. Our previous results suggest that dasatinib targets del17 CLL lymphocytes which are the CLL patients with the worst prognosis. Here we present mechanistic evidence that dasatinib induces endoplasmic reticulum stress and autophagy in CLL lymphocytes. Furthermore we provide evidence suggesting that autophagy mediates resistance to the drugs, process that is modulated by p53. © 2010 Elsevier Ltd.

Author supplied keywords

Cite

CITATION STYLE

APA

Amrein, L., Soulières, D., Johnston, J. B., & Aloyz, R. (2011). P53 and autophagy contribute to dasatinib resistance in primary CLL lymphocytes. Leukemia Research, 35(1), 99–102. https://doi.org/10.1016/j.leukres.2010.05.029

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free